These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24662823)

  • 1. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy.
    Kim B; Wang S; Lee JM; Jeong Y; Ahn T; Son DS; Park HW; Yoo HS; Song YJ; Lee E; Oh YM; Lee SB; Choi J; Murray JC; Zhou Y; Song PH; Kim KA; Weiner LM
    Oncogene; 2015 Feb; 34(9):1083-93. PubMed ID: 24662823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression.
    Lee BS; Kang S; Kim KA; Song YJ; Cheong KH; Cha HY; Kim CH
    Cell Death Dis; 2014 Apr; 5(4):e1159. PubMed ID: 24722284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
    Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current state of molecularly targeted drugs targeting HGF/Met.
    Yano S; Nakagawa T
    Jpn J Clin Oncol; 2014 Jan; 44(1):9-12. PubMed ID: 24371262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
    Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
    Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
    Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
    J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
    Qi J; McTigue MA; Rogers A; Lifshits E; Christensen JG; Jänne PA; Engelman JA
    Cancer Res; 2011 Feb; 71(3):1081-91. PubMed ID: 21266357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
    Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
    Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
    Nanjo S; Yamada T; Nishihara H; Takeuchi S; Sano T; Nakagawa T; Ishikawa D; Zhao L; Ebi H; Yasumoto K; Matsumoto K; Yano S
    PLoS One; 2013; 8(12):e84700. PubMed ID: 24386407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired Resistance to a MET Antibody
    Pollmann SE; Calvert VS; Rao S; Boca SM; Madhavan S; Horak ID; Kjaer A; Petricoin EF; Kragh M; Poulsen TT
    Mol Cancer Ther; 2018 Jun; 17(6):1259-1270. PubMed ID: 29545332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
    Sugano T; Seike M; Noro R; Soeno C; Chiba M; Zou F; Nakamichi S; Nishijima N; Matsumoto M; Miyanaga A; Kubota K; Gemma A
    Mol Cancer Ther; 2015 Nov; 14(11):2433-40. PubMed ID: 26351321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
    Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
    J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.
    Brown WS; Tan L; Smith A; Gray NS; Wendt MK
    Mol Cancer Ther; 2016 Sep; 15(9):2096-106. PubMed ID: 27371729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.
    Lee JM; Kim B; Lee SB; Jeong Y; Oh YM; Song YJ; Jung S; Choi J; Lee S; Cheong KH; Kim DU; Park HW; Han YK; Kim GW; Choi H; Song PH; Kim KA
    Oncogene; 2014 Jan; 33(1):34-43. PubMed ID: 23208509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
    Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
    Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
    Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
    Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
    Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
    Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.
    Miyajima N; Tsutsumi S; Sourbier C; Beebe K; Mollapour M; Rivas C; Yoshida S; Trepel JB; Huang Y; Tatokoro M; Shinohara N; Nonomura K; Neckers L
    Cancer Res; 2013 Dec; 73(23):7022-33. PubMed ID: 24121490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.